Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?
Macdougall
Iain C
IC
Department of Renal Medicine, King's College Hospital, London, UK. iainc.macdougall@virgin.net
Roche
Alison
A
Rossert
Jerome
J
Casadevall
Nicole
N
Francois
Patrick
P
Kemeny
D Michael
DM
D000368:Aged; D000906:Antibodies / Q000032:analysis; D000911:Antibodies, Monoclonal; D000068817:Epoetin Alfa; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006397:Hematinics / Q000009:adverse effects*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced*; D017701:Reticulocyte Count; D019233:Retreatment
D000906:Antibodies; D000911:Antibodies, Monoclonal; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D000068817:Epoetin Alfa